-
The CXO industry is now deeply adjusted, and some pharmaceutical companies have more than doubled
Time of Update: 2022-05-01
The company expects that in 2021, the net profit attributable to shareholders of listed companies (referred to as net profit) will increase by more than 40% year-on-year, exceeding 1 billion yuan .
517 billion yuan; the net profit attributable to shareholders of listed companies increased by 76.
-
Pharmaceutical e-commerce and other sub-sectors are strengthening, and the industry: The opportunity for the pharmaceutical industry to lay out has come!
Time of Update: 2022-05-01
In the early trading of March 4th, the pharmaceutical sector performed outstandingly, among which the e-commerce sector rose sharply, including the daily limit of multiple stocks such as Common Pharmaceutical, Intel Group, Neptunus Bio, and Kaikai Industry .
-
Digestive tract vibrating capsule system approved!
Time of Update: 2022-05-01
Among them, in 2021, the State Food and Drug Administration approved a total of 35 innovative medical device products, an increase of 35% year-on-year and a record high .
-
Chia Tai Qingjiang Dexmedetomidine Hydrochloride Injection is approved for production and deemed to have been reviewed
Time of Update: 2022-05-01
Partial review of dexmedetomidine hydrochloride injection Source: Minet Consistency Evaluation Database Before CP Qingjiang, the dexmedetomidine hydrochloride injection of 14 domestic companies has passed or is deemed to pass the consistency evaluation, including Yangzijiang, Hengrui, Beite, Enhua, Nanjing CP Tianqing, etc.
-
Today, off-label drug use is officially implemented
Time of Update: 2022-05-01
According to the content of the announcement, at least four preconditions can be considered to be the premise of hyperadaptive drug use: ①The drug has evidence-based medical evidence; ②There is no other safer, more effective, economical and reasonable treatment method; ③The patient has informed consent; ④The hospital has established related management mechanisms .
-
A batch of pharmaceutical companies have stopped production and revoked certificates!
Time of Update: 2022-05-01
On February 22, the Shandong Provincial Food and Drug Administration announced that due to the expiration of the license validity period and the failure to re-issue the license, Weihai Renji Traditional Chinese Medicine Decoction Pieces Factory, Shandong Puhua Pharmaceutical Co.
-
Paclitaxel liposome was selected as the preferred combination drug for multiple radiotherapy and chemotherapy in the new edition of "Chinese Guidelines for Radiation Therapy of Esophageal Cancer"
Time of Update: 2022-05-01
According to guideline recommendations, for operable esophageal cancer, neoadjuvant chemoradiotherapy followed by surgery is the standard treatment; for inoperable esophageal cancer, concurrent chemoradiotherapy is the only radical plan; postoperative adjuvant radiotherapy can improve the local control rate and survival of some patients.
-
250 companies disclosed performance reports, the net profit of this pharmaceutical company increased by more than 1800%
Time of Update: 2022-05-01
In addition to Rejing Bio, among the pharmaceutical and biological companies that have disclosed their performance reports, Sunshine Guojian's net profit has also doubled .
-
Jiangsu: Shuanghuanglian oral liquid, vitamin B6 injection and other 15 drugs to be withdrawn from the Internet
Time of Update: 2022-05-01
On March 4, the Jiangsu Provincial Public Resource Trading Center issued a notice to withdraw the drugs listed on the Internet.
If there is any objection, the enterprise must appeal through the Jiangsu Provincial Public Resource Trading Platform (Drug Classified Procurement-Other-Revocation of the Online Appeal (202203)) within the publicity period, and submit relevant certification materials .
-
Another pharmaceutical company showed its 2021 transcript, and its total revenue and R&D investment doubled!
Time of Update: 2022-05-01
Excluding upfront payments for newly signed license agreements, core R&D spending in 2021 was $252 million compared to $139.
It will continue to invest in R&D and advance its in-house pipeline with global rights to achieve its mission of benefiting patients around the world .
-
Hong Kong SAR Government: The overall supply of anti-epidemic proprietary Chinese medicines is stable
Time of Update: 2022-05-01
(Finish) The Food and Health Bureau (Food and Health Bureau) of the Hong Kong Special Administrative Region Government stated on the 8th that it has noticed the recent surge in demand for anti-epidemic Chinese patent medicines in the market, stressed that the overall supply is stable, and called on merchants not to hoard anti-epidemic Chinese patent medicines, while the public can follow the actual situation.
-
Several new drugs have been approved!
Time of Update: 2022-05-01
Fosun Kite: FKC889 Clinical Approval On March 2, Fosun Pharma announced that Fosun Kite, a subsidiary of the company, recently received a request from the State Food and Drug Administration to approve its CD19-targeted autologous CAR-T cell therapy product FKC889 for treatment Approval for a clinical trial in adult patients with relapsed or refractory mantle cell lymphoma (r/r MCL) after prior second-line therapy or more .
-
A large number of drugs are transferred out of local medical insurance!
Time of Update: 2022-05-01
For example, the notice issued by the Qinghai Provincial Medical Insurance Bureau on printing and distributing the supplementary drug digestion catalogue in Qinghai Province makes it clear that the remaining 98 varieties will be transferred in 2022, and medical insurance and work-related injury insurance will be suspended from January 1, 2023 .
-
Since 2022, six pharmaceutical company chairmen have resigned
Time of Update: 2022-05-01
On March 4, Fangsheng Pharmaceutical announced that due to personal reasons, Zhang Qinghua, the company's chairman and general manager, applied to resign from his positions as the company's chairman (legal representative), director, director of the strategic development committee of the board of directors and general manager .
-
Sinopharm China Biopolio Inactivated Vaccine Passes WHO Pre-certification
Time of Update: 2022-05-01
On March 1, the State Food and Drug Administration announced that recently, the World Health Organization stated that the Sabin strain (Vero cell) inactivated polio vaccine (sIPV) of Sinopharm China Beijing Institute of Biological Products has passed pre-qualification and can be used for United Nations system procurement .
-
12 batches of drugs in Jiangxi failed the sampling inspection!
Time of Update: 2022-05-01
The announcement shows that in order to strengthen the supervision of drug quality and ensure the safety of public medication, in accordance with the "Drug Administration Law" and related laws and regulations and the Jiangxi Provincial Drug Sampling Plan, the drug regulatory departments and inspection agencies at all levels in Jiangxi Province will conduct inspections on the production, operation and use of drugs in the province.
-
Enrico Ticagrelor Tablets Obtained Drug Registration Certificate
Time of Update: 2022-04-30
On March 9, 2022, Anglikang announced that the company's Ticagrelor tablets had recently received the "Drug Registration Certificate" issued by the NMPA .
It is used for patients with acute coronary syndrome (ACS) or patients with a history of myocardial infarction and at least one high risk factor for atherothrombotic events.
-
What are the prospects for each of the three major segments of biopharmaceuticals?
Time of Update: 2022-04-30
According to the "2020 China Gene Engineering Drug Project Business Plan" released by the Xinsijie Industry Research Center, in 2019, the global market size has exceeded 2 trillion yuan, and China's genetic engineering drug market share in the global market is relatively Small, the scale in the same year was only about 280 billion yuan, and the future market growth potential is huge .
-
Pfizer launches clinical trial of COVID-19 drug Paxlovid in children aged 6-17
Time of Update: 2022-04-30
CompilationTom LeePfizer today announced that it has initiated a Phase 2/3 clinical trial of Paxlovid, an oral antiviral drug for COVID-19, in children aged 6 to 17 .
Pfizer begins trial of COVID drug Paxlovid in kids 6 to 17
-
Focusing on women's health, ovarian cancer patients usher in 3 new drugs with reduced prices!
Time of Update: 2022-04-30
Among them, the imported drug niraparib has become more “close to the people”, whether patients with BRCA mutations or newly diagnosed advanced ovarian cancer patients can receive niraparib first-line maintenance treatment and enjoy medical insurance reimbursement .
